Wire · opportunities
Korean biotech Quracle seeks U.S. Phase 2b trial of CU06 in 156 DME patients
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 November 2026 · Fusion42 review
Quracle, a Korean biotech firm, has applied to the U.S. FDA to conduct a Phase 2b clinical trial of its oral drug CU06 (Rivasterat) for diabetic macular edema, enrolling 156 patients to evaluate visual acuity improvements over 24 weeks.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your drug development in retinal diseases can now access a less invasive oral therapy pathway in the U.S. starting Phase 2b trials. This opens a chance to sidestep injection-based treatments and attract patients seeking convenience.
◆ Coverage
1 source · 20 Nov 2026
◆ Related on Wire
◆ Topics